Polymorphonuclear neutrophils contain a number of proteins and peptides that have antimicrobial activities. Among the best characterized are bactericidal-and permeabilityincreasing protein (BPI) (3, 13) , the defensins (9) , and azurocidin (a cationic antimicrobial protein of 37 kDa [CAP37]) (11) . We recently reported the isolation and characterization of a novel lipopolysaccharide (LPS)-binding protein called CAP18 (4, 5) . CAP18 was identified and purified on the basis of its ability to agglutinate erythrocytes coated with LPS, especially Re LPS and lipid A (6) . Early studies demonstrated that semipurified preparations of CAP had antibacterial activity (14) . Cloning and sequencing of the cDNA of rabbit CAP18 led to the discovery of a C-terminal 37-amino-acid fragment, designated CAP18106_142 with LPSbinding activity (8) . Here we demonstrate that CAP18106 142 and a related, slightly shorter fragment have potent antimicrobial activities against both gram-negative and gram-positive bacteria. This activity is highly dependent on structure, because other truncated segments of the 37-amino-acid fragment are inactive. Because antibacterial activity is maintained in the presence of serum, CAP18106142 or a derivative thereof may have therapeutic potential.
MATERIALS AND METHODS Antibacterial activity. (i) Bacterial strains. Salmonella typhimurium LT2 (smooth), Salmonella minnesota R595 (Re mutant), Escherichia coli 09:K39 (K+ and K-strains), E. coli 0111:B4, Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus (methicillin susceptible and methicillin resistant), and Candida albicans were used. The last five strains were clinical isolates.
(ii) Bactericidal assay. All strains were grown in Tryptosoy broth (Eiken Co., Tokyo, Japan tion was carried out by preparative HPLC. The peptides were applied to the column in a minimum volume of either 10 to 20% acetyl hydroxide or 0.1% trifluoroacetic acid (TFA). Gradient elutions were performed by using linear gradients of buffer A (0.1% TFA and H20) and buffer B (0.1% TFA and CH3CN) at a flow rate of 8.0 ml/min with UV detection at 220 nm. Fractions were collected at 1.5-to 2.5-min intervals and were inspected by analytical HPLC in the reversed-phase mode as stated above. Fractions judged to be of high purity were pooled and lyophilized. The final products were characterized by analytical HPLC and amino acid analysis. The purified peptides were also subjected to fast atom bombardment mass spectrometry and yielded the expected parent M+H ions within acceptable limits (+1 mass unit). Erythrocyte agglutination assay. One milliliter of 1% erythrocytes (human type 0, C3H/HeN mouse, or sheep erythrocytes) were sensitized and mixed with 0.2 ml of Re LPS solution (100 ,ug/ml), and the mixture was incubated at 37°C for 30 min; this was followed by washing with PBS. Fifty microliters of a 1.0% suspension of sensitized erythrocytes was mixed with 50 ,ul of a twofold serial dilution of CAP or CAP peptides in a U-bottom microtiter plate, and the mixture was incubated at 37°C for 1 h. The activity of CAP was expressed as the minimum agglutinating concentration.
Assay of reactive nitrogen intermediates. The murine macrophage cell line RAW 264.7 (obtained from the American Type Culture Collection) was used to produce reactive nitrogen intermediates. Cells were cultured at 106/ml in RPMI 1640 medium-2.5% FCS in 24-well plates in the presence or absence of different concentrations of LPS.
After 24 h of incubation at 37°C, the cell-free supernatant was collected and tested for the presence of reactive nitrogen intermediates. Accumulation of nitrite in the medium was measured by a colorimetric assay on the basis of the Griess reaction with sodium nitrite standards. Sample (50 ,ul) was mixed with 50 ,lI of Griess reagent (1% sulfanilamide, 0.1% naphthalene diamine dihydrochloride, 2.5% H3PO4), and after 10 min at room temperature the A570 was read.
RESULTS
LPS binding by CAP18106 142 peptides. In a previous report (7) a large series of CAP18106_142-derived peptides was studied for LPS binding and neutralization of LPS-induced nitric oxide release from murine macrophages. From that initial work, four peptides were selected for in-depth studies: native CAP18106 142, a more active peptide with a truncation at the C-terminal end of CAP18106_142 (peptide CAP18106_137), and two inactive peptides, CAP1816-114 and CAP18117_142. Table   1 shows the sequences and the LPS-binding activities of the four peptides tested for their antimicrobial activities. Table 1 also shows the high degree of correlation of LPS binding with inhibition of LPS-induced production of nitric oxide.
CAP18106 142 peptides inhibit growth of diverse strains of gram-negative bacteria. Because CAP18106_142 was originally shown to bind and cause agglutination of erythrocytes coated with rough mutant LPS, antimicrobial activity against the rough mutant strain S. minnesota R595 was initially evaluated. Figure 1A presents the dose-responses of the four peptides on S. minnesota R595 CFU. Non-LPS-binding peptides CAP181o6-114 and CAP18117142 were not active, whereas the LPS-binding peptides CAP18106142 and CAP18106_137 had significant antibacterial activities (IC50, <100 ng/ml; 20 nM).
Next, the activity against a smooth enterobacterial strain,
S. typhimunium, was tested (Fig. 1B) aeruginosa (IC50, <250 ng/ml; 50 nM) and K pneumoniae (IC50, <540 ng/ml; 100 nM) (data not shown).
Two other control experiments were carried out with the LPS-nonbinding peptides. In the first case ( Fig. 2A) , pep- In further studies, the susceptibilities of encapsulated strains were examined. Figure 3 compares the activity of peptide CAP18106142 against encapsulated (K+) and nonencapsulated (K-) E. coli 09:K39. The K-strain was less susceptible to the peptide (IC50, 700 ng/ml; 140 nM) than the K+ strain (IC50, 140 ng/ml; 30 nM).
Finally, the effect of serum on killing was studied, because other antimicrobial peptides require nonphysiological conditions (e.g., hypotonic buffers and acidic pH [5.0 to 5.5]) to exhibit activity. The addition of 10% FCS to the proliferation assay performed in RPMI 1640 medium resulted in only a modest decrease in antibacterial activity (13 to 17%; data not shown).
CAP181o6-142 peptides inhibit growth of diverse strains of gram-positive bacteria. Table 2 18106_142 against both methicillin-susceptible (IC50, 940 ng/ ml; 190 nM) and methicillin-resistant (IC50, 1,000 ng/ml; 200 nM) S. aureus strains was compared with its activity against E. coli (IC50, 500 ng/ml; 100 nM).
Activity of CAP18106 142 against other microorganisms. The highly active antibacterial peptides CAP18106142 and CAP18106137 were inactive against C. albicans over the range of 0 to 20 ,ug/ml (data not shown) and multiple-drugresistant M. tuberculosis and two strains of Mycobacterium avium (from L. Heifitz, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colo.) (data not shown).
DISCUSSION
In the present study we defined the potent antimicrobial activities of peptides derived from the rabbit granulocyte protein CAP18. The cloning of rabbit CAP18 revealed that this molecule comprises two domains (8) . The N-terminal domain is highly homologous to porcine cathelin originally purified as a cysteine protease inhibitor (12) . Purified human CAP18 also demonstrates significant cysteine protease activity (17) . The C-terminal 37-amino-acid domain (CAP18106142) of CAP18 was identified as the LPS-binding domain when HPLC fractions were tested for their capacity to inhibit LPSinduced nitrogen radical production (5) . Previously, a large series of CAP18106-142-derived peptides was studied for LPS binding and neutralization of LPS-induced nitric oxide release from murine macrophages (7) . That work demonstrated that truncation of the N terminus of the protein resulted in loss of LPS-binding activity. (15) . From the results of the present study and previous work, it is clear that the cationic nature of these agents is not the sole determinant required for the permeabilizing activity.
The activity of CAP18 can be contrasted with that of BPI, which was originally shown to have antibacterial activity against a variety of gram-negative bacteria, with no activity against gram-positive bacteria or fungi (13) . BPI demonstrates high-affinity binding to LPS (3) and can apparently inhibit the activity of LPS in vitro (10) . Both the aminoterminal fragment (rBPI23) and the holoprotein (BP155) inhibit encapsulated E. coli. While both BPI55 and rBPI23 inhibited the growth of a rough mutant strain of Proteus mirabilis, only rBPI23 inhibited growth of the wild-type smooth organism. Neither rBPI23 nor holoprotein BPI55 inhibit the growth of gram-positive S. aureus (16) .
Three other families of granulocyte proteins exhibit LPSbinding and antimicrobial activities. These include the 13-amino-acid C-terminal peptide of bovine indolicidin (2), the 30-to 35-amino-acid family of defensins (9) , and azurocidin (CAP37) (11) . The indolicidin peptide and the defensins only inhibit the growth of gram-positive and gram-negative bacteria in hypotonic medium, thus distinguishing them from CAP18106142 A recent report (11) 
